Biodeposito di amiloide cardiaca

ID studio #: NCT05521503

condizione: Amiloidosi cardiaca

stato: reclutamento

Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by cardiac amyloidosis and therapeutic interventions.

risultati: https://clinicaltrials.gov/ct2/show/results/NCT05521503

ultimo aggiornamento: 22 Febbraio 2024

data d'inizio: Dicembre 21, 2021

completamento previsto: Dicembre 2027

ultimo aggiornamento: 22 Agosto 2023

taglia / iscrizione: 400

descrizione dello studio: This is a prospective study enrolling patients referred for or undergoing cardiac amyloidosis or cardiovascular treatment at the University of Kentucky. The study aims to facilitate the discovery of novel diagnostic biomarkers and therapeutic targets and improve the pathophysiological understanding of cardiac amyloidosis.

risultati primari:

• Discover and quantify the concentration of novel diagnostic and prognostic biomarkers
  Use biospecimens procured from patients with cardiac amyloidosis to identify diagnostic surrogate biomarkers using discovery proteomics. The serum levels will be compared between confirmed ATTR and non-ATTR heart failure patients and a diagnostic threshold will be established.
• 12/21/2021-12/31/2027
  

criterio di inclusione:

criteri di esclusione: criteri:

Patients without a cardiovascular or amyloidosis diagnosis, under 18 years of age.

sponsor: Andrew Kolodziej

contatti: Andrew R Kolodziej, MD, (859) 562-0902, [email protected]

investigatori: Andrew R Kolodziej, MD,University Of Kentucky

sedi dei centri di prova: Stati Uniti

• Stati Uniti, Kentucky
  University of Kentucky
  Andrew Kolodziej, MD, 859-562-0902, [email protected]